Etanercept for rheumatoid arthritis
Record ID 32006000988
English
Authors' objectives:
Etanercept, a biologic tumor necrosis factor (TNF) antagonist, is a recombinant human TNF receptor p75 fusion protein that inhibits proinflammatory cytokine activity. It is prescribed, either alone or in combination with methotrexate, to reduce the signs and symptoms of rheumatoid arthritis (RA) and to slow the progression of joint damage in patients with moderately to severely active disease.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=1881
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.